Therapy of systemic vasculitis

Neurologic Clinics

Volumn 15, Issue 4, 1997, Pages 973-991

  Calabrese, L H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; TACROLIMUS;

AVASCULAR NECROSIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CATARACT; DRUG HYPERSENSITIVITY; FRACTURE; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MYOPATHY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMIC VASCULITIS;

EID: 0031469685     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70359-5     Document Type: Article

References (46)

1. V. Agnello P.L. Romain Mixed cryoglobulinemia secondary to hepatitis C Rheum Clin North Am 22 1996 1 22
2. G.L. Baker L.E. Kahl B.C. Zee Malignancy following treatment of rheumatoid arthritis with cyclophosphamide arthritis with cyclophosphamide: Long-term case-control follow-up study Am J Med 83 1987 1 9
3. J.A.M. Baltus J.W. Boersma A.P. Hartman The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective study Ann Rheum Dis 42 1983 368 373
4. D.T. Boumpas Mechanism of action. Boumpas DT (moderator): Glucocorticoid therapy for immune mediated diseases: Basic and clinical correlates Ann Intern Med 19 1993 1198 1208
5. D.T. Boumpas H.A. Austin E.M. Vaughn Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy Ann Intern Med 119 1993 366 369
6. Calabrese LH. Intravenous immunoglobulin therapy for systemic necrotizing vasculitis. In Lee ML, Strand V. Intravenous Immunoglobulins in Clinical Practice. New York, Marcel Dekker, in press
7. L.H. Calabrese G.S. Hoffman L. Guillevin Therapy resistant systemic necrotizing vasculitis: Polyarteritis, Churg-Strauss syndrome, Wegener's granulomatosis, and hypersensitivity vasculitis group disorders Rheum Dis Clin North Am 21 1995 41 57
8. J.M. Cash G.S. Hoffman Glucocorticoids R. Rich Clinical Immunology 1994 Mosby–Year Book St. Louis 1947
9. B.N. Cronstein Molecular mechanisms of methotrexate action in inflammation Inflammation 16 1992 59 71
10. B.N. Cronstein M.A. Eberle H.E. Gruber Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells Proc Natl Acad Sci U S A 88 1991 2441 2445
11. A.M. Denman P.M. Brooks Antirheumatic therapy P.J. Maddinson D.A. Isenberg P. Woo Oxford Textbook of Rheumatology 1993 Oxford University Press Oxford 329 349
12. G.F. Duna G.S. Hoffman Immunosuppression: New perspectives in the treatment of systemic vasculitides Ann Med Intern 148 1994 581 594
13. L.H. Fraiser S. Kanekal J.P. Kehrer Cyclophosphamide toxicity, characterizing and avoiding the problem Drugs 42 1991 781 795
14. E.K. Garber P.T. Jan R. Bluestone Realistic guidelines of corticosteroid therapy Semin Arthritis Rheum 11 1981 231 255
15. J. Gerrard Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults Med J Aust 162 1995 233 235
16. L. Guillevin F. Lhote B. Jarrousse Treatment of polyarteritis nodosa and Churg- Strauss syndrome Ann Med Intern 143 1992 405 416
17. L. Guillevin F. Lhote R. Gherarde Treatment of virus associated vasculitis Curr Opin Rheumatol, Vol 9 1997 31 36
18. H.J. Haga D. D'Cruz R. Asherson Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis Ann Rheum Dis 51 1992 885 888
19. G.S. Hoffman R.Y. Leavitt T.A. Fleisher Treatment of Wegener's granulomatosis with intermittent high dose intravenous cyclophosphamide Am J Med 89 1989 403 410
20. G.S. Hoffman R.Y. Leavitt G.S. Kerr Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate Arthritis Rheum 37 1994 578 582
21. G.S. Hoffman Treatment of resistant Takayasu's arteritis Rheum Clin North Am 21 1995 73 80
22. J.H. Hofnagle A.M. DiBisceglie The treatment of chronic viral hepatitis N Engl J Med 336 1997 347 356
23. G.G. Hunder S.G. Sheps G.L. Allen Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis. Comparison in a prospective study Ann Intern Med 82 1975 613 618
24. D.R.W. Jayne V.L.M. Esnault C.M. Lockwood ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin J Autoimmunity 6 1993 207 219
25. G.S. Kerr T.A. Fleisher C.W. Hallahan Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis Arthritis Rheum 36 1993 365 372
26. L. Klassen L.H. Calabrese R.M. Larer Intravenous immunoglobulin in rheumatic disease Rheum Dis Clin North Am 22 1996 155 174
27. H.F. Klinefelter W.L. Winkenuerder T. Bledsoe Single daily dose prednisone therapy JAMA 241 1979 2721 2723
28. J. Kovarsky Clinical pharmacology and toxicology of cyclophosphamide Emphasis on use in rheumatic diseases Semin Arthritis Rheum 12 1983 359 372
29. J.M. Kremer G.S. Alarcon Lightfoot R.W. Jr Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity Arthritis Rheum 37 1994 316 328
30. C.A. Langford The legacy of chronic immunosuppressive therapy for systemic vasculitis Curr Op Rheum, Vol 7 1997 41 48
31. C. Langford M.C. Sneller New developments in the treatment of Wegener's granulomatosis, polyarteritis nodosa, microscopy polyarteritis and Churg-Strauss Curr Opin Rheum, Vol 7 1997 26 30
32. J.H. Lewis E. Schiff Methotrexate-induced chronic liver injury: Guidelines for detection and prevention Am J Gastroenterol 88 1988 1337 1345
33. C.M. Lockwood Approaches to specific immunotherapy for systemic vasculitis Semin Neurol 14 1994 387 392
34. C.M. Lockwood New treatment for systemic vasculitis: The role of intravenous immunoglobulin Clin Exp Immunol 104 1994 77 82
35. J.D. O'Duffy E. Matteson K. Calamia Alpha-interferon treatment in Behcet's disease [abstract] Arthritis Rheum 39 suppl 1996 S227
36. N. Rasmussen D.R.W. Jayne D. Abramowicz European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials Sarcoidosis 13 1996 29 34
37. C. Richter E. Schanbel E. Csernok Treatment of ANCA-associated systemic vasculitis with high-dose intravenous immunoglobulin Arthritis Rheum 37 1994 S353
38. M.C. Sneller G.S. Hoffman C. Talar-Williams An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone Arthritis Rheum 38 1995 608 613
39. C.A. Stegeman Cohen Tervaert J.W. P.E. DeJong Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis N Engl J Med 335 1996 16 20
40. V. Strand E. Keystone F. Breedveld Biologic agents for the treatment of rheumatoid arthritis Rheum Clin North Am 22 1996 117 132
41. C. Talar-Williams T.M. Hijazi M.M. Walther Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis Ann Intern Med 124 1996 477 484
42. E. Tatsis M. Muhler A. Schnaubec Treatment of Churg-Strauss syndrome with interferon alpha [abstract] Arthritis Rheum 39 suppl 1996 S64
43. D.R. Thomas J.S. Dover R.D.R. Camp Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole J Am Acad Dermatol 17 1987 1055 1056
44. R.M. Valente D.L. Conn Current therapies for systemic vasculitis Semin Neurol 14 1994 380 386
45. R.L. Wilder Effects on nonlymphoid inflammatory cells. Boumpas DT (moderator): Glucocorticoid therapy for immune mediated diseases:basic and clinical correlates Ann Intern Med 119 1993 1198 1208
46. D.E. Yocum Cyclosporine, FK506, rapamycin and other immunomodulators Rheum Dis Clin North Am 22 1996 133 154